First Time Loading...

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 5.95 USD 4.75% Market Closed
Updated: May 15, 2024

Editas Medicine Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Editas Medicine Inc
Total Equity Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Total Equity Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Editas Medicine Inc
NASDAQ:EDIT
Total Equity
$294.4m
CAGR 3-Years
-23%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Total Equity
$10.4B
CAGR 3-Years
-7%
CAGR 5-Years
N/A
CAGR 10-Years
9%
Gilead Sciences Inc
NASDAQ:GILD
Total Equity
$17.5B
CAGR 3-Years
-3%
CAGR 5-Years
-4%
CAGR 10-Years
3%
Amgen Inc
NASDAQ:AMGN
Total Equity
$5B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-14%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Equity
$17.6B
CAGR 3-Years
26%
CAGR 5-Years
32%
CAGR 10-Years
29%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Equity
$27B
CAGR 3-Years
31%
CAGR 5-Years
23%
CAGR 10-Years
28%

See Also

What is Editas Medicine Inc's Total Equity?
Total Equity
294.4m USD

Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Total Equity amounts to 294.4m USD.

What is Editas Medicine Inc's Total Equity growth rate?
Total Equity CAGR 5Y
6%

Over the last year, the Total Equity growth was -7%. The average annual Total Equity growth rates for Editas Medicine Inc have been -23% over the past three years , 6% over the past five years .